(Philadelphia) – Bruce Willner, Chief Science Officer at Graphene Frontiers, discussed graphene-based biosensors at the Regional Commercialization Summit in Philadelphia today. Co-sponsored by Pennsylvania BIO and the New Jersey Technology Council, the summit featured keynote speaker, Jane Holmes Hollingsworth, a panel discussion with top local investors and a series of fast pitches for several university-based life sciences innovations.
Chris Laing, VP, Science & Technology at the University City Science Center, which hosted the event, described Philadelphia’s startup ecosystem as a rainforest. “The Science Center must be a keystone species,” he said. “We give and get more by collaborating.”
The graphene-based biosensor ranked as a highly mature technology compared to many of the university innovations. Graphene Frontiers recently won an NSF SBIR Phase II grant to develop a continuous production line for large-area graphene sheets. Graphene, the subject of the 2010 Nobel Prize in Physics, is a single atomic layer of carbon. It is considered a “miracle material” for its outstanding strength, flexibility, conductivity and impermeability.
Graphene Frontiers is an advanced materials and nanotechnology company based at the University City Science Center in Philadelphia. The company welcomes collaboration with researchers and corporations working on similar technologies. Graphene Frontiers’ next event will be the Graphene Commercialization and Applications Summit on December 10-11 in San Mateo, CA.